Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
capsid
Biotech
Lilly saves gene therapy biotech with $18M upfront deal
Sangamo can earn up to $1.4 billion in fees and milestones, as well as tiered royalties, if Lilly opts to pursue all five possible targets.
Darren Incorvaia
Apr 3, 2025 6:00pm
AbbVie pays $70M to expand Capsida collab into eye disease
Feb 23, 2023 5:00am
Novartis eyes next-gen AAV therapies in $1.75B Voyager pact
Mar 8, 2022 1:15am
Novartis, Sarepta tap Dyno to unearth new gene therapy vectors
May 11, 2020 7:00am
Passage Bio adds more programs, tech and time to UPenn deal
May 7, 2020 7:30am
Taysha debuts with $30M, 15 gene therapy programs
Apr 29, 2020 8:00am
